Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estianeptine
- Development stage
- Preclinical
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TNX-4300 (estianeptine) is an oral small molecule therapeutic being developed by Tonix Pharmaceuticals for the treatment of major depressive disorder (MDD), bipolar disorder, Alzheimer's disease, and Parkinson's disease. It is the (S)-enantiomer of tianeptine and acts as a dual agonist of peroxisome proliferator-activated receptors (PPAR) β/δ and γ. Unlike racemic tianeptine, TNX-4300 is designed to be free of µ-opioid receptor activity, which is associated with the (R)-enantiomer. The drug's mechanism of action involves restoring neuroplasticity and neurogenesis in neuronal tissue, representing a first-in-class approach to repairing atrophied neuronal connections in psychiatric and neurodegenerative conditions.
- Other names
- (S)-tianeptineS-tianeptine
02
Targets
PPARD (Peroxisome proliferator–activated receptor delta)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on estianeptine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estianeptine.